X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (30) 30
index medicus (30) 30
oncology (28) 28
female (25) 25
middle aged (22) 22
adult (19) 19
aged (19) 19
disease-free survival (18) 18
breast neoplasms - drug therapy (17) 17
breast neoplasms - pathology (14) 14
cancer (12) 12
aged, 80 and over (11) 11
breast cancer (11) 11
chemotherapy (10) 10
trastuzumab (10) 10
antineoplastic combined chemotherapy protocols - therapeutic use (9) 9
treatment outcome (9) 9
antineoplastic combined chemotherapy protocols - adverse effects (8) 8
breast neoplasms - mortality (7) 7
double-blind method (7) 7
efficacy (7) 7
fluorouracil - administration & dosage (7) 7
hematology, oncology and palliative medicine (7) 7
male (7) 7
melanoma (7) 7
therapy (7) 7
angiogenesis (6) 6
carcinoma (6) 6
expression (6) 6
paclitaxel (6) 6
safety (6) 6
antibodies, monoclonal, humanized (5) 5
antimitotic agents (5) 5
antineoplastic agents (5) 5
antineoplastic agents, hormonal - administration & dosage (5) 5
breast neoplasms - metabolism (5) 5
drug administration schedule (5) 5
infusions, intravenous (5) 5
kaplan-meier estimate (5) 5
metastasis (5) 5
survival (5) 5
survival analysis (5) 5
trial (5) 5
animals (4) 4
antibodies, monoclonal, humanized - administration & dosage (4) 4
antibodies, monoclonal, humanized - adverse effects (4) 4
antineoplastic agents - adverse effects (4) 4
cancer therapies (4) 4
capecitabine (4) 4
care and treatment (4) 4
cells (4) 4
chemotherapy, adjuvant (4) 4
drug therapy (4) 4
estradiol - administration & dosage (4) 4
estradiol - analogs & derivatives (4) 4
neoadjuvant therapy (4) 4
neoplasm metastasis (4) 4
neoplasm staging (4) 4
oncology, experimental (4) 4
proportional hazards models (4) 4
prospective studies (4) 4
research (4) 4
time factors (4) 4
vasculogenic mimicry (4) 4
young adult (4) 4
abridged index medicus (3) 3
activation (3) 3
adenocarcinoma - drug therapy (3) 3
anastrozole (3) 3
antibodies, monoclonal - adverse effects (3) 3
antibodies, monoclonal - therapeutic use (3) 3
antineoplastic agents - administration & dosage (3) 3
antineoplastic agents, hormonal - adverse effects (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
bevacizumab (3) 3
cell line, tumor (3) 3
cyclophosphamide - administration & dosage (3) 3
deoxycytidine - administration & dosage (3) 3
deoxycytidine - adverse effects (3) 3
deoxycytidine - analogs & derivatives (3) 3
fluorouracil - adverse effects (3) 3
fluorouracil - analogs & derivatives (3) 3
follow-up studies (3) 3
injections, intramuscular (3) 3
medicine, general & internal (3) 3
melanoma - blood supply (3) 3
melanoma - pathology (3) 3
mice (3) 3
multicenter (3) 3
open-label (3) 3
plus (3) 3
postmenopausal women (3) 3
postmenopause (3) 3
quality of life (3) 3
receptor, erbb-2 - genetics (3) 3
receptor, erbb-2 - metabolism (3) 3
receptors, estrogen - metabolism (3) 3
subcutaneous (3) 3
survival rate (3) 3
tumors (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2010, Volume 375, Issue 9712, pp. 377 - 384
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 6, pp. 640 - 647
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 9, pp. 869 - 878
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1389 - 1398
Summary Background In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EQ-5D | QUESTIONNAIRE QLQ-C30 | ONCOLOGY | SCORES | RELIABILITY | EUROPEAN-ORGANIZATION | CANCER | VALIDITY | Prospective Studies | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Oximes - administration & dosage | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Time Factors | DNA Mutational Analysis | Imidazoles - therapeutic use | MAP Kinase Kinase Kinases - antagonists & inhibitors | Genetic Predisposition to Disease | Administration, Oral | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Risk Factors | MAP Kinase Kinase Kinases - metabolism | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Indoles - adverse effects | Intention to Treat Analysis | Quality of Life | Indoles - therapeutic use | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Oximes - therapeutic use | Pyridones - administration & dosage | Melanoma - genetics | Skin Neoplasms - mortality | Surveys and Questionnaires | Skin Neoplasms - pathology | Drug Administration Schedule | Treatment Outcome | Melanoma - secondary | Disease-Free Survival | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Sulfonamides - adverse effects | Pyridones - therapeutic use | Pyridones - adverse effects | Care and treatment | Hospitals | Metastasis | Gene mutations | Comparative analysis | Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2008, Volume 26, Issue 12, pp. 2013 - 2019
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2013, Volume 31, Issue 17, pp. 2128 - 2135
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 19, pp. 1789 - 1801
A blinded trial involving patients with resected stage III melanoma showed that adjuvant pembrolizumab every 3 weeks for a year was associated with a 1-year... 
HIGH-RISK MELANOMA | SURVIVAL | MEDICINE, GENERAL & INTERNAL | ANTI-PD-1 THERAPY | EORTC 18952 | TUMOR BURDEN | CUTANEOUS MELANOMA | PHASE-3 TRIAL | PEGYLATED INTERFERON-ALPHA-2B | NODE-POSITIVE MELANOMA | IPILIMUMAB | Skin Neoplasms - drug therapy | Humans | Middle Aged | Male | Adjuvants, Immunologic - adverse effects | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Adjuvants, Immunologic - therapeutic use | Skin Neoplasms - surgery | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Survival Rate | Disease-Free Survival | B7-H1 Antigen - antagonists & inhibitors | Melanoma - drug therapy | Intention to Treat Analysis | Quality of Life | Aged | B7-H1 Antigen - analysis | Infusions, Intravenous | Melanoma - surgery | Neoplasm Staging | Melanoma - mortality | Diagnosis | Drug therapy | Patients | Health aspects | Melanoma | Medical research | Lymphatic system | Risk groups | PD-1 protein | Committees | Metastasis | Survival | Skin cancer | Pembrolizumab | Hospitals | Motivation | PD-L1 protein | Myositis | Death | Mutation | Tumors | Cancer | Index Medicus | Abridged Index Medicus | Placebos | Placebos (Medicine) | Adjuvant treatment of cancer | Tractament adjuvant del càncer
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2009, Volume 27, Issue 33, pp. 5538 - 5546
Purpose Cross-talk between human epidermal growth factor receptors and hormone receptor pathways may cause endocrine resistance in breast cancer. This trial... 
EFFICACY | ONCOLOGY | RANDOMIZED PHASE-II | TAMOXIFEN RESISTANCE | GROWTH | MCF-7 CELLS | COMBINATION | INHIBITOR | EXPRESSION | ESTROGEN-RECEPTOR | PLUS | Triazoles - administration & dosage | Triazoles - adverse effects | Postmenopause - drug effects | Receptors, Estrogen - metabolism | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma - mortality | Receptors, Progesterone - genetics | Breast Neoplasms - metabolism | Receptors, Progesterone - metabolism | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Invasiveness - pathology | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Carcinoma - pathology | Carcinoma - secondary | Carcinoma - drug therapy | Receptors, Estrogen - genetics | Double-Blind Method | Drug Administration Schedule | Risk Assessment | Biomarkers, Tumor - analysis | Antineoplastic Agents, Hormonal - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Breast Neoplasms - pathology | Quinazolines - adverse effects | Survival Analysis | Breast Neoplasms - mortality | Aged | Biomarkers, Tumor - genetics | Carcinoma - metabolism | Neoplasm Staging | Nitriles - adverse effects | Index Medicus | Carcinoma | Quinazolines | Breast Neoplasms | Life Sciences | Immunology | Triazoles | Postmenopause | Nitriles | Antineoplastic Agents, Hormonal | Tumor Markers, Biological | Receptors, Estrogen | Neoplasm Invasiveness | Antineoplastic Combined Chemotherapy Protocols | Receptor, erbB-2 | Receptors, Progesterone | Kaplan-Meiers Estimate
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2010, Volume 28, Issue 30, pp. 4594 - 4600
Journal Article